Vimian Group AB VIMIAN
OMXSTO · Sweden · Health Technology
SEK 35.65+0.05 (+0.14%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
In recent weeks, global markets have been buoyed by optimism surrounding a potential U.S.-Iran peace agreement, easing oil prices, and the continued momentum of AI-linked stocks. Amid this positive sentiment and record highs in several major indices, investors are increasingly on the lookout for opportunities to identify stocks that may be trading below their estimated value. In such an environment, a good stock often combines strong fundamentals with growth potential that is not yet fully...
As of April 2026, European markets have faced a challenging environment, with the pan-European STOXX Europe 600 Index declining by 2.54% amid geopolitical tensions and economic uncertainties. Despite these headwinds, investors often seek opportunities in undervalued stocks that may offer potential for growth when market conditions stabilize.
Vimian Group AB (FRA:0V0) reports robust revenue growth and strategic market expansions, despite challenges in MedTech and Diagnostics segments.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.